27 results about "Regulator gene" patented technology

The p300 inhibitor specifically regulates the expression of genes that induce fibrosis, thereby acting only on fibrotic tissues and reducing the risk of adverse effects on normal tissues. Because the inhibitor blocks multiple fibrotic signaling pathways, it may be effective for fibrosis in various organs such as the liver, lungs, and kidneys. In addition, by modulating gene expression, the inhibitor has the potential to address the fundamental cause of the fibrotic process. The present invention is characterized in that bronopol is first identified as a specific example of such a p300 inhibitor. In particular, bronopol is an FDA-approved drug with established safety, and therefore is expected to reduce the time and cost required for conducting clinical trials.

The present disclosure provides an engineered nucleic acid sequence comprising a gene cassette, the gene cassette comprising one or more regulator genes, the regulator genes including an iadR gene, and at least three catabolic pathway genes downstream from the one or more regulator genes, the at least three catabolic pathway genes including an iadC gene, an iadD gene, and an iadE gene, wherein the engineered nucleic acid sequence is free of an iadA gene and iadB gene. The disclosure also provides bacteria cells comprising the engineered nucleic acid sequence, wherein the bacteria cell is capable of degrading indole-3-acetic acid. Methods for degrading auxin, controlling auxin, and promoting plant growth and root development are provided, comprising providing the bacteria cell and allowing the bacteria cell to interact with roots of a plant.

Described herein are small molecule splicing modulator compounds that modulate splicing of mRNA, such as pre-mRNA, encoded by genes, pharmaceutical compositions comprising the same, and methods of the small molecule splicing modulator compounds for modulating splicing and treating disease and conditions. In one aspect, disclosed herein are small molecule splicing modulators having a structure of Formula (II), or pharmaceutically acceptable salts thereof.

Articles, compositions, kits, and methods relating to nanostructures, including synthetic nanostructures, are provided. Certain embodiments described herein include structures having a core-shell type arrangement; for instance, a nanostructure core may be surrounded by a shell including a material, such as a lipid bilayer, and may include other components such as oligonucleotides. In some embodiments, the structures, when introduced into a subject, can be used to deliver nucleic acids and / or can regulate gene expression. Accordingly, the structures described herein may be used to diagnose, prevent, treat or manage certain diseases or bodily conditions. In some cases, the structures are both a therapeutic agent and a diagnostic agent.

Provided is a use of a reagent capable of regulating the expression of the Ncbp2 gene or regulating the activity of an expression product of the Ncbp2 gene in the preparation of a drug for preventing and / or treating diseases or conditions related to cardiomyocyte injury in a subject.

The present invention provides DNA molecules and constructs comprising their nucleotide sequences useful for modulating gene expression in plants and plant cells. Transgenic plants, plant cells, plant parts, seeds, and commodity products comprising the DNA molecules operably linked to heterologous transcribable polynucleotides are also provided, as are methods of use thereof.

The present disclosure generally relates to, inter alia, a new class of chimeric Notch receptors containing a fully humanized transcriptional effector, engineered to modulate gene expression and cellular activities in a ligand-dependent manner. The new chimeric Notch receptors surprisingly retain the ability to transduce signals in response to ligand binding despite that the Notch extracellular subunit (NEC), which includes the negative regulatory region (NRR) previously believed to be essential for the functioning of Notch receptors is completely absent. In addition, the new receptors described herein incorporate an extracellular oligomerization domain to promote oligomer formation of the chimeric receptors. Also provided are compositions and methods useful for producing such receptors, nucleic acids encoding same, engineered cells genetically modified with the nucleic acids, as well as methods for modulating an activity of a cell and / or for the treatment of various diseases such as cancers.

The present invention provides DNA molecules and constructs comprising nucleotide sequences thereof useful for modulating gene expression in plants and plant cells. Also provided are transgenic plants, plant cells, plant parts, seeds, and commodities comprising DNA molecules operably linked to a heterologous transcribable polynucleotide, and methods of use thereof.

The present invention relates to a compound for regulating the expression level and / or activity of the BRAF gene, and a composition comprising same. The compound and the composition are useful for preventing, treating, or alleviating BRAF-related diseases, disorders, and conditions.

Compositions and methods for modifying genomic DNA sequences are provided. The methods produce double-stranded breaks (DSBs) at pre-determined target sites in a genomic DNA sequence, resulting in mutation, insertion, and / or deletion of DNA sequences at the target site(s) in a genome. Compositions comprise DNA constructs comprising nucleotide sequences that encode a Cms1 protein operably linked to a promoter that is operable in the cells of interest. The DNA constructs can be used to direct the modification of genomic DNA at pre-determined genomic loci. Methods to use these DNA constructs to modify genomic DNA sequences are described herein. Additionally, compositions and methods for modulating the expression of genes are provided. Compositions comprise DNA constructs comprising a promoter that is operable in the cells of interest operably linked to nucleotide sequences that encode a mutated Cms1 protein with an abolished ability to produce DSBs, optionally linked to a domain that regulates transcriptional activity. The methods can be used to up-or down-regulate the expression of genes at predetermined genomic loci.

The invention relates to the field of biological medicine, and relates to application of a reagent capable of regulating the expression of an Ncbp2 gene or regulating the activity of an expression product of the Ncbp2 gene in preparation of a medicine, and the medicine is used for preventing and / or treating diseases or symptoms related to myocardial cell injury in a subject.

An isolated or purified antisense oligomer for modulating mRNA translation of the OPA1 gene transcript or part thereof which has a modified backbone structure and sequences with at least 75% sequence identity to the isolated or purified antisense oligomer.

Provided herein are systems of modulating gene expression, methods of use thereof, and cells engineered thereof for the purpose of differentiating cells, for example hematopoietic cells.

We disclose bispecific nucleic acid molecules comprising at least two double stranded inhibitory ribonucleic acid (RNA) molecules adapted to silence by RNA interference either the same gene or different genes to enhance silencing thereby modulating gene expression wherein said at least two double stranded inhibitory RNA molecules are linked by a DNA linker molecule; and a treatment regimen comprising administration of at least two inhibitory monospecific RNA molecules adapted to silence at least two cardiovascular gene targets.

The application discloses application of overexpression of PtoCC1 gene in biomass increase of poplar and belongs to the technical field of plant genetic engineering. The PtoCC1 gene is introduced into poplar, and the transgenic poplar overexpressing PtoCC1 is obviously higher and thicker compared with the wild type, and the number of xylem cells and biomass are obviously increased, which indicates that the PtoCC1 gene is a key regulation gene for regulating formation of poplar wood and has important application value in the fields of forest genetic engineering and clone forestry.

The present application provides materials and methods for treating a patient with one or more conditions associated with SCN9A whether ex vivo or in vivo. In addition, the present application provides materials and methods for editing and / or modulating the expression of SCN9A gene in a cell by genome editing.

The invention discloses a preparation method and application of a conditionally replicated lentiviral vector, and the preparation method comprises the following steps: based on an attenuated HIV-1 (R8.71) without an auxiliary protein coding regulatory gene, inserting a tetracycline regulated transcriptional activator rtTA and a tetO-containing cis-response element TRE, and carrying out function inactivation on a transcriptional regulation system Tat-TAR of the attenuated HIV-1 (R8.71), so as to obtain the conditionally replicated lentiviral vector. The conditional replicating type lentivirus vector plasmid is obtained; the auxiliary protein coding regulatory gene comprises a Vif gene, a Vpr gene, a Vpu gene and a Nef gene; the nucleotide sequence of the transcription activator rtTA is as shown in SEQ ID NO. 1; 1, and the nucleotide sequence of the cis-response element TRE is as shown in SEQ ID NO. 2. The conditionally replicated lentiviral vector provided by the invention meets the requirements of'catalog of pathogenic microorganisms infected by humans', can be tested in a P2-level biosafety laboratory with the qualification easier to obtain than P3, is used as a positive control virus for RCL detection, and greatly improves the flux of RCL release detection while meeting the requirements of a quality system for data integrity.

The invention belongs to the technical field of agricultural biology, and particularly relates to application of a stevia rebaudiana low-phosphorus response gene PHR family in improving the content of glycoside in stevia rebaudiana. The invention provides application of a stevia rebaudiana low-phosphorus response gene PHR family in improving the content of glycoside in stevia rebaudiana, the stevia rebaudiana low-phosphorus response gene PHR family comprises a SrPHR1 gene and a SrPHR13 gene, and the relative content of rebaudioside C, steviobioside, rebaudioside D and total glycoside is improved by overexpressing the SrPHR1 gene; the relative content of stevioside and rebaudioside A is reduced through overexpression of the SrPHR1 gene; the relative contents of rebaudioside A, rebaudioside C and total glycosides are increased by overexpressing the SrPHR13 gene; the relative content of stevioside and rebaudioside D is reduced through overexpression of the SrPHR13 gene. The invention clarifies the influence of low phosphorus on the yield and quality of stevia rebaudiana, and preliminarily explores the application value of the phosphorus regulatory gene in improving the quality of stevia rebaudiana.

This invention discloses a PtoSAUR74 gene related to the adventitious root formation ability of poplar and its applications. The nucleotide sequence of the coding region of the PtoSAUR74 gene disclosed in this invention is shown in SEQ ID NO.1, and the protein sequence is shown in SEQ ID NO.2. Overexpression of the PtoSAUR74 gene in poplar significantly inhibits the length, number, and growth rate of adventitious roots, indicating that the PtoSAUR74 gene is a key regulatory gene affecting the development of adventitious roots in poplar, providing a key target for precise molecular regulation of poplar root growth. This invention also discloses a method for regulating the adventitious root formation ability of poplar. By regulating the expression of the PtoSAUR74 gene, adventitious root formation can be directly inhibited, providing new technical means and theoretical basis for the genetic improvement of poplar.

This invention discloses a method for controlling the intracellular localization of sgRNA and regulating gene expression. It presents an NES-Ms2-Lans5 photocontrol element, comprising, in a 5' to 3' sequence, an NES gene fragment, a Ms2 gene fragment, and a Lans5 gene fragment, each gene fragment connected by a linker. The invention also discloses a photocontrolled CRISPR assembly including the aforementioned photocontrol element, a gene targeting element, and a gene regulatory element. Based on the photocontrolled CRISPR assembly, a method for photoregulating the expression of target genes is also provided. This invention provides the first strategy for gene editing by regulating the location of sgRNA in cells, achieving the activation and expression of specific genes.

This invention provides a method for controlling the immunogenicity of manipulated cells. [Solution] The method is, (a) Obtaining isolated cells, (b) To produce engineered cells by introducing into the isolated cells (i) a nucleic acid containing an inducible RNA polymerase promoter operably linked to an shRNA sequence targeting an immunosuppressive factor, and (ii) a nucleic acid containing a promoter operably linked to a transactivator element corresponding to the inducible RNA polymerase promoter, (c) Exposing the manipulated cells to an exogenous factor for activating the transactivator element, thereby controlling the immunogenicity of the manipulated cells, Includes.

The present invention provides a composition comprising one or more polynucleotides capable of upregulating expression of alpha- 1 anti-trypsin (Al AT). In an embodiment, the one or more polynucleotides of the present invention upregulates the expression of Al AT by downregulating antisense RNA that regulates the Al AT gene. In an embodiment, the one or more polynucleotides comprises an siRNA or an shRNA. In an embodiment, one or more polynucleotides of the present invention is delivered by a nanoparticle such as an exosome that encapsulates the one or more polynucleotides. The present invention also provides a method of treatment of Al AT deficiency related diseases or disorders using any embodiment of the one or more polynucleotides of the present invention.

The application belongs to the field of agricultural biotechnology, and particularly relates to application of a low-phosphorus response gene SPX family of Stevia rebaudiana in improving glycoside content of Stevia rebaudiana. The application provides application of a low-phosphorus response gene SPX family of Stevia rebaudiana in improving glycoside content of Stevia rebaudiana, wherein the low-phosphorus response gene SPX family of Stevia rebaudiana comprises SrSPX2 a gene and SrSPX-RING4 a gene, a nucleotide sequence of the SrSPX2 gene is shown as SEQ ID NO: 1, and a nucleotide sequence of the SrSPX-RING4 gene is shown as SEQ ID NO: 2. The application determines the influence of low phosphorus on yield and quality of Stevia rebaudiana, and explores potential application value of a phosphorus regulation gene in improving quality of Stevia rebaudiana.

The subject matter disclosed herein is directed to modulating STAT3 gene expression using siRNA compositions and methods directed to affecting key cell populations supporting the growth and metastasis of cancer to affect the beneficial treatment, remission or removal of the underlying tumor in a patient.

The application discloses application of a substance for regulating CdLAC15 expression level in regulating lignin polymerization degree. A first aspect of an embodiment of the application provides application of a substance for regulating CdLAC15 expression level and / or activity in regulating lignin polymerization degree of a target plant. It is found in the embodiment of the application that expression of a CdLAC15 gene of Camellia chingii can regulate the polymerization degree of lignin. When the gene is overexpressed in a wild-type Arabidopsis thaliana as a model plant, the lignin polymerization degree in tissues such as pericarp, leaf and stem of the Arabidopsis thaliana is obviously increased. Therefore, the lignin polymerization degree in parts such as pericarp of a plant can be regulated by a reagent for regulating the expression level of the CdLAC15 gene, and the reagent has important application value in breeding and the like.

A compound for improving the gene editing specificity and application thereof. Specifically disclosed is a compound represented by formula I or a use of a pharmaceutically acceptable salt thereof. The compound and the pharmaceutically acceptable salt thereof are used for preparing an inhibitor, a composition, or a formulation for inhibiting gene editing and / or improving the gene editing specificity. The structure of the formula I is as stated in the description. The compound can significantly improve the accuracy of CRISPR gene editing, thereby providing a simple and high-efficient policy for accurate gene editing.